Literature DB >> 33541283

Distinct roles for the RNA-binding protein Staufen1 in prostate cancer.

Kristen A Marcellus1,2, Tara E Crawford Parks1,2, Shekoufeh Almasi1,2, Bernard J Jasmin3,4.   

Abstract

BACKGROUND: Prostate cancer is one of the most common malignant cancers with the second highest global rate of mortality in men. During the early stages of disease progression, tumour growth is local and androgen-dependent. Despite treatment, a large percentage of patients develop androgen-independent prostate cancer, which often results in metastases, a leading cause of mortality in these patients. Our previous work on the RNA-binding protein Staufen1 demonstrated its novel role in cancer biology, and in particular rhabdomyosarcoma tumorigenesis. To build upon this work, we have focused on the role of Staufen1 in other forms of cancer and describe here the novel and differential roles of Staufen1 in prostate cancer.
METHODS: Using a cell-based approach, three independent prostate cancer cell lines with different characteristics were used to evaluate the expression of Staufen1 in human prostate cancer relative to control prostate cells. The functional impact of Staufen1 on several key oncogenic features of prostate cancer cells including proliferation, apoptosis, migration and invasion were systematically investigated.
RESULTS: We show that Staufen1 levels are increased in all human prostate cancer cells examined in comparison to normal prostate epithelial cells. Furthermore, Staufen1 differentially regulates growth, migration, and invasion in the various prostate cancer cells assessed. In LNCaP prostate cancer cells, Staufen1 regulates cell proliferation through mTOR activation. Conversely, Staufen1 regulates migration and invasion of the highly invasive, bone metastatic-derived, PC3 prostate cells via the activation of focal adhesion kinase.
CONCLUSIONS: Collectively, these results show that Staufen1 has a direct impact in prostate cancer development and further demonstrate that its functions vary amongst the prostate cancer cell types. Accordingly, Staufen1 represents a novel target for the development of much-needed therapeutic strategies for prostate cancer.

Entities:  

Keywords:  Invasion; Migration; Proliferation; Prostate cancer; RNA-binding proteins; Staufen1

Mesh:

Substances:

Year:  2021        PMID: 33541283      PMCID: PMC7863451          DOI: 10.1186/s12885-021-07844-2

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  120 in total

1.  Staufen1 localizes to the mitotic spindle and controls the localization of RNA populations to the spindle.

Authors:  Sami Hassine; Florence Bonnet-Magnaval; Louis Philip Benoit Bouvrette; Bellastrid Doran; Mehdi Ghram; Mathieu Bouthillette; Eric Lecuyer; Luc DesGroseillers
Journal:  J Cell Sci       Date:  2020-07-23       Impact factor: 5.285

Review 2.  The focal adhesion kinase--a regulator of cell migration and invasion.

Authors:  Christof R Hauck; Datsun A Hsia; David D Schlaepfer
Journal:  IUBMB Life       Date:  2002-02       Impact factor: 3.885

3.  Molecular characterization of human prostate carcinoma cell lines.

Authors:  Adrie van Bokhoven; Marileila Varella-Garcia; Christopher Korch; Widya U Johannes; E Erin Smith; Heidi L Miller; Steven K Nordeen; Gary J Miller; M Scott Lucia
Journal:  Prostate       Date:  2003-11-01       Impact factor: 4.104

4.  Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.

Authors:  Walter Gregory Roberts; Ethan Ung; Pamela Whalen; Beth Cooper; Catherine Hulford; Christofer Autry; Daniel Richter; Earling Emerson; Jing Lin; John Kath; Kevin Coleman; Lili Yao; Luis Martinez-Alsina; Marianne Lorenzen; Martin Berliner; Michael Luzzio; Nandini Patel; Erika Schmitt; Susan LaGreca; Jitesh Jani; Matt Wessel; Eric Marr; Matt Griffor; Felix Vajdos
Journal:  Cancer Res       Date:  2008-03-15       Impact factor: 12.701

5.  Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.

Authors:  Ker Yu; Celine Shi; Lourdes Toral-Barza; Judy Lucas; Boris Shor; Jae Eun Kim; Wei-Guo Zhang; Robert Mahoney; Christine Gaydos; Luanna Tardio; Sung Kyoo Kim; Roger Conant; Kevin Curran; Joshua Kaplan; Jeroen Verheijen; Semiramis Ayral-Kaloustian; Tarek S Mansour; Robert T Abraham; Arie Zask; James J Gibbons
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701

6.  hiCLIP reveals the in vivo atlas of mRNA secondary structures recognized by Staufen 1.

Authors:  Yoichiro Sugimoto; Alessandra Vigilante; Elodie Darbo; Alexandra Zirra; Cristina Militti; Andrea D'Ambrogio; Nicholas M Luscombe; Jernej Ule
Journal:  Nature       Date:  2015-03-18       Impact factor: 49.962

Review 7.  PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance.

Authors:  Merritt P Edlind; Andrew C Hsieh
Journal:  Asian J Androl       Date:  2014 May-Jun       Impact factor: 3.285

8.  Staufen1 impairs stress granule formation in skeletal muscle cells from myotonic dystrophy type 1 patients.

Authors:  Aymeric Ravel-Chapuis; Amanda Klein Gunnewiek; Guy Bélanger; Tara E Crawford Parks; Jocelyn Côté; Bernard J Jasmin
Journal:  Mol Biol Cell       Date:  2016-03-30       Impact factor: 4.138

9.  E2F1 induces TINCR transcriptional activity and accelerates gastric cancer progression via activation of TINCR/STAU1/CDKN2B signaling axis.

Authors:  Tong-Peng Xu; Yan-Fen Wang; Wei-Liang Xiong; Pei Ma; Wen-Yu Wang; Wen-Ming Chen; Ming-De Huang; Rui Xia; Rong Wang; Er-Bao Zhang; Yan-Wen Liu; Wei De; Yong-Qian Shu
Journal:  Cell Death Dis       Date:  2017-06-01       Impact factor: 8.469

Review 10.  Application of Prostate Cancer Models for Preclinical Study: Advantages and Limitations of Cell Lines, Patient-Derived Xenografts, and Three-Dimensional Culture of Patient-Derived Cells.

Authors:  Takeshi Namekawa; Kazuhiro Ikeda; Kuniko Horie-Inoue; Satoshi Inoue
Journal:  Cells       Date:  2019-01-20       Impact factor: 6.600

View more
  5 in total

1.  Phosphomimicry on STAU1 Serine 20 Impairs STAU1 Posttranscriptional Functions and Induces Apoptosis in Human Transformed Cells.

Authors:  Yulemi Gonzalez Quesada; Florence Bonnet-Magnaval; Luc DesGroseillers
Journal:  Int J Mol Sci       Date:  2022-07-01       Impact factor: 6.208

2.  High Level of Staufen1 Expression Confers Longer Recurrence Free Survival to Non-Small Cell Lung Cancer Patients by Promoting THBS1 mRNA Degradation.

Authors:  Florence Bonnet-Magnaval; Leïla Halidou Diallo; Valérie Brunchault; Nathalie Laugero; Florent Morfoisse; Florian David; Emilie Roussel; Manon Nougue; Audrey Zamora; Emmanuelle Marchaud; Florence Tatin; Anne-Catherine Prats; Barbara Garmy-Susini; Luc DesGroseillers; Eric Lacazette
Journal:  Int J Mol Sci       Date:  2021-12-25       Impact factor: 5.923

Review 3.  The multifunctional RNA-binding protein Staufen1: an emerging regulator of oncogenesis through its various roles in key cellular events.

Authors:  Shekoufeh Almasi; Bernard J Jasmin
Journal:  Cell Mol Life Sci       Date:  2021-10-11       Impact factor: 9.261

Review 4.  Internal Ribosome Entry Site (IRES)-Mediated Translation and Its Potential for Novel mRNA-Based Therapy Development.

Authors:  Rita Marques; Rafaela Lacerda; Luísa Romão
Journal:  Biomedicines       Date:  2022-08-02

Review 5.  Targeting Protein Kinases and Epigenetic Control as Combinatorial Therapy Options for Advanced Prostate Cancer Treatment.

Authors:  Soghra Bagheri; Mahdie Rahban; Fatemeh Bostanian; Fatemeh Esmaeilzadeh; Arash Bagherabadi; Samaneh Zolghadri; Agata Stanek
Journal:  Pharmaceutics       Date:  2022-02-25       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.